- ICL Group Ltd.’s (ICL) shares climbed 6% after the company reported third-quarter 2024 adjusted earnings per share of $0.11, surpassing the Zacks Consensus Estimate of $0.08.
- Shares of $Aramark(ARMK-W)$ (ARMK) fell 1.1% after the company posted fourth-quarter fiscal 2024 revenues of $4,416.95 million, missing the Zacks Consensus Estimate of $4,439.46 million.
- AbbVie Inc.’s (ABBV) shares plummeted 12.6% after its experimental schizophrenia drug failed to show a statistically significant improvement in symptoms during two Phase 2 trials.
- Shares of Sapiens International Corp. N.V. (SPNS) plunged 26.2% after posting third-quarter 2024 revenues of $137.03 million, lagging the Zacks Consensus Estimate of $140.34 million.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AbbVie Inc. (ABBV) : Free Stock Analysis Report
Aramark (ARMK) : Free Stock Analysis Report
ICL Group Ltd. (ICL) : Free Stock Analysis Report
Sapiens International Corporation N.V. (SPNS) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。